Adverse reactions including abnormal variations in clinical laboratory values were observed in 414 of 5,958 patients (6.95%) in clinical and post marketing surveillance studies. Adverse effects associated with Cilnidipine included dizziness, flushing, headache, hypotension, peripheral edema, tachycardia, palpitations, gastrointestinal disturbances. Increased frequency of micturition, lethargy, eye pain, depression, ischemic chest pain, cerebral or myocardial ischemia, transient blindness. Rashes, fever, abnormal liver function, gingival hyperplasia, myalgia, tremor, impotence may be seen. Serious adverse effects included liver dysfunction and jaundice with unknown frequency. Liver dysfunction accompanied by elevated AST (GOT), ALT (GPT), γ-GTP etc., jaundice may appear which should be observed thoroughly. If abnormality is found, discontinue administration and appropriate measures should be taken. Thrombocytopenia (<0.1%) may occur, administration should be discontinued and appropriate measures should be taken immediately if abnormalities are observed. (See Table 3.)
Click on icon to see table/diagram/image